Literature DB >> 15068402

Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.

M R Mohammadi1, L Kashani, S Akhondzadeh, E S Izadian, S Ohadinia.   

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a common disorder of childhood that affects 3-6% of school children. Conventional stimulant medications are recognized as useful symptomatic treatments by both specialists and parents. Nevertheless, approximately 30% of ADHD children treated with them do not respond adequately or cannot tolerate the associated adverse effects. Such difficulties highlight the need for alternative, safe and effective medications in the treatment of this disorder. Theophylline is a psychomotor stimulant most widely used as a broncodilator. Purinergic modulation may be therapeutically beneficial in the treatment of psychiatric disorders. We hypothesized that theophylline would be beneficial for the treatment of ADHD and report results of a trial of theophylline compared with methylphenidate for the treatment of ADHD. A total of 32 children with ADHD as defined by DSM IV were randomized to theophylline and methylphenidate dosed on an age and weight-adjusted basis at 4 mg/kg/day (under 12 years) and 3 mg/kg/day theophylline (over 12 years) (group 1) and 1 mg/kg/day methylphenidate (group 2) for a 6-week double-blind and randomized clinical trial. The principal measure of the outcome was the Teacher and Parent ADHD Rating Scale. Patients were assessed by a child psychiatrist, at baseline and at 14, 28 and 42 days after start of the medication. No significant differences were observed between theophylline and methylphenidate on the Parent and Teacher Rating Scale scores over the trial (t = 0.49, d.f. = 24 P = 0.62 and t = 0.19, d.f. = 24 P = 0.54 respectively). Although the number of dropouts in the methylphenidate group was higher than the theophylline group, there was no significant difference between the two protocols in terms of the dropouts. In addition, headaches were observed more often in the methylphenidate group. The results suggest that theophylline may be a useful for the treatment of ADHD. In addition, a tolerable side-effect profile is one of the advantages of theophylline in the treatment of ADHD. Nevertheless, our study is small and our results would need to be confirmed in a larger study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068402     DOI: 10.1111/j.1365-2710.2004.00545.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  9 in total

Review 1.  Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis.

Authors:  Sarah C O S Padilha; Suzane Virtuoso; Fernanda S Tonin; Helena H L Borba; Roberto Pontarolo
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-19       Impact factor: 4.785

2.  Restless legs syndrome as a possible predictor for psychiatric disorders in parents of children with ADHD.

Authors:  Susanne Steinlechner; Norbert Brüggemann; Vera Sobottka; Alexander Benthien; Birte Behn; Christine Klein; Gabriele Schmid; Rebekka Lencer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-09-04       Impact factor: 5.270

3.  Drug therapy of attention deficit hyperactivity disorder: current trends.

Authors:  Avinash De Sousa; Gurvinder Kalra
Journal:  Mens Sana Monogr       Date:  2012-01

Review 4.  Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis.

Authors:  Erica Ramstad; Ole Jakob Storebø; Trine Gerner; Helle B Krogh; Mathilde Holmskov; Frederik L Magnusson; Carlos R Moreira-Maia; Maria Skoog; Camilla Groth; Donna Gillies; Morris Zwi; Richard Kirubakaran; Christian Gluud; Erik Simonsen
Journal:  Scand J Child Adolesc Psychiatr Psychol       Date:  2018-07-10

5.  Investigating drug repositioning opportunities in FDA drug labels through topic modeling.

Authors:  Halil Bisgin; Zhichao Liu; Reagan Kelly; Hong Fang; Xiaowei Xu; Weida Tong
Journal:  BMC Bioinformatics       Date:  2012-09-11       Impact factor: 3.169

6.  Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co-administration: Through circadian cycle modification or appetite enhancement?

Authors:  Seyed-Ali Mostafavi; Mohammad Reza Mohammadi; Payam Hosseinzadeh; Mohammad Reza Eshraghian; Shahin Akhondzadeh; Mohammad Javad Hosseinzadeh-Attar; Elham Ranjbar; Seyed Mohammad-Ali Kooshesh; Seyed-Ali Keshavarz
Journal:  Iran J Psychiatry       Date:  2012

7.  Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial.

Authors:  Mohammad Reza Mohammadi; Seyed Ali Mostafavi; Seyed Ali Keshavarz; Mohammad Reza Eshraghian; Payam Hosseinzadeh; Mohammad Javad Hosseinzadeh-Attar; Seyed Mohammad Ali Kooshesh; Maryam Chamari; Shahin Akhondzadeh
Journal:  Iran J Psychiatry       Date:  2012

Review 8.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09

Review 9.  Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.

Authors:  Hyeong-Min Lee; Yuna Kim
Journal:  Schizophr Res Treatment       Date:  2016-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.